Healthcare resource utilization and costs among psoriasis patients treated with biologics, overall and by disease severity

Psoriasis

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)

J Am Acad Dermatol.

Strober B, Gooderham M, de Jong EMGJ, Kimball AB, Langley RG, Lakdawala N, Goyal K, Lawson F, Langholff W, Hopkins L, Fakharzadeh S, Srivastava B, Menter A

doi: 10.1016/j.jaad.2017.08.051.

Psoriasis

A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents

JAMA Dermatol.

Bronckers IMGJ, Paller AS, West DP, Lara-Corrales I, Tollefson MM, Tom WL, Hogeling M, Belazarian L, Zachariae C, Mahé E, Siegfried E, Blume-Peytavi U, Szalai Z, Vleugels RA, Holland K, Murphy R, Puig L, Cordoro KM, Lambert J, Alexopoulos A, Mrowietz U, Kievit W, Seyger MMB, Psoriasis Investigator Group, the Pediatric Dermatology Research Alliance, and the European Working Group on Pediatric Psoriasis

doi: 10.1001/jamadermatol.2019.4835.

PsoriasisPsoriatic Arthritis

The risk of treated anxiety and treated depression among patients with psoriasis and PsA treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database

J Eur Acad Dermatol Venereol.

Vasilakis-Scaramozza C, Persson R, Hagberg KW, Jick S

doi: 10.1111/jdv.16231.

Psoriasis

Efficacy of Risankizumab in Patients with Moderate-to-Severe Plaque Psoriasis by Baseline Demographics, Disease Characteristics and Prior Biologic Therapy: An Integrated Analysis of the Phase III UltIMMa-1 and UltIMMa-2 Studies

J Eur Acad Dermatol Venereol.

Strober B, Menter A, Leonardi C, Gordon K, Lambert J, Puig L, Photowala H, Longcore M, Zhan T, Foley P

doi: 10.1111/jdv.16521.

Psoriasis

Prevalence of HPV genital infection in patients with moderate-to-severe psoriasis undergoing systemic treatment with immunosuppressive agents or biologics

Eur J Dermatol

Offidani A, Radi G, Bianchi L, Cannavò SP, Conti A, Gesuita R, Salaffi F, Talamonti M, Campanati A

doi: 10.1684/ejd.2021.4121

Psoriasis

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)

J Eur Acad Dermatol Venereol.

Seneschal J, Lacour JP, Bewley A, Faurby M, Paul C, Pellacani G, De Simone C, Horne L, Sohrt A, Augustin M, Hammond E, Reich K

doi: 10.1111/jdv.16568.

Rheumatoid Arthritis

Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.

Clin Exp Rheumatol.

Yang M, Galebach PJ, Signorovitch JE, Garg V

Psoriasis

Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomised VOYAGE 1 and VOYAGE 2 studies

Br J Dermatol.

Reich K, Papp KA, Armstrong AW, Wasfi Y, Li S, Shen YK, Randazzo B, Song M, Kimball AB

doi: 10.1111/bjd.17454.

Melanoma and Skin CancerPsoriasis

Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.

J Am Acad Dermatol.

Asgari MM, Ray GT, Geier JL, Quesenberry CP

doi: 10.1016/j.jaad.2016.10.006.

Related content

Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR)

A Comparison of Psoriasis Severity in Pediatric Patients Treated With Methotrexate vs Biologic Agents

The risk of treated anxiety and treated depression among patients with psoriasis and PsA treated with apremilast compared to biologics, DMARDs and corticosteroids: a cohort study in the United States MarketScan database

Efficacy of Risankizumab in Patients with Moderate-to-Severe Plaque Psoriasis by Baseline Demographics, Disease Characteristics and Prior Biologic Therapy: An Integrated Analysis of the Phase III UltIMMa-1 and UltIMMa-2 Studies

Prevalence of HPV genital infection in patients with moderate-to-severe psoriasis undergoing systemic treatment with immunosuppressive agents or biologics

A multinational, prospective, observational study to estimate complete skin clearance in patients with moderate-to-severe plaque PSOriasis treated with BIOlogics in a REAL world setting (PSO-BIO-REAL)

Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.

Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomised VOYAGE 1 and VOYAGE 2 studies

Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population.